Transplantation, AutologousPeripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsGraft vs Host DiseaseBone Marrow TransplantationCombined Modality TherapyHematopoietic Stem Cell MobilizationTreatment OutcomeMelphalanCyclophosphamideMultiple MyelomaStem CellsHematologic NeoplasmsLeukapheresisGranulocyte Colony-Stimulating FactorSalvage TherapyLymphoma, Non-HodgkinHematopoietic Stem CellsRemission InductionAntigens, CD34EtoposideDisease-Free SurvivalRecurrenceBlood Component RemovalMyeloablative AgonistsAntineoplastic AgentsGraft SurvivalHodgkin DiseaseBusulfanSurvival RateCytarabineThiotepaImmunosuppressive AgentsSurvival AnalysisBone Marrow PurgingCarmustineWhole-Body IrradiationRetrospective StudiesTissue DonorsAntineoplastic Agents, AlkylatingVincristineDoxorubicinCord Blood Stem Cell TransplantationAmyloidosisTime FactorsIfosfamideTransplantation ChimeraPrognosisFollow-Up StudiesChemotherapy, AdjuvantDexamethasoneHistocompatibility TestingLymphomaHistocompatibilityAntibodies, Monoclonal, Murine-DerivedLeukemia, Myeloid, AcuteLymphoma, Mantle-CellEmbryonic Stem CellsBoronic AcidsMesenchymal Stem Cell TransplantationHematopoiesisPyrazinesNeoplasm, ResidualLeukemiaLymphoma, FollicularPodophyllotoxinProspective StudiesNeoplasmsCytomegalovirus InfectionsPrednisoneBlood CellsAdult Stem CellsMyelodysplastic SyndromesThalidomideCarboplatinLymphoma, T-Cell, PeripheralBlood Cell CountVidarabineDose-Response Relationship, DrugFeasibility StudiesCisplatinFatal OutcomeKidney TransplantationNeutropeniaHematologic DiseasesInduction ChemotherapyMitoxantroneBone MarrowTransplantationDrug Administration ScheduleAutograftsAcute DiseaseLiver TransplantationCell DifferentiationIdarubicinInfection